In the phase III, TROPICS-2 study presented by Hope Rugo el al, #Sacituzumab_govitecan (SG) significantly improved OS (median 14.4 vs 11.2 mo; HR, 0.79; P=0.020), compared to physician’s choice of chemotherapy (TPC) in metastatic HR+/HER2- #breast_cancer. In a previous report this year, SG has also shown a significant PFS improvement. In addition, SG significantly improved ORR and QoL vs TPC with a manageable toxicity profile.
.png)